◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 0907

Elegance Optical International Holdings Limited (0907) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Medical Instruments & Supplies · DATA UPDATED 2026-08-10

Elegance Optical International Holdings Limited (0907) operates in the Medical Instruments & Supplies industry and is headquartered in Central, Hong Kong with about 43 employees. Its market capitalization is roughly HKD 53 million. In the fiscal year ended 2026-03-31, 0907 reported HKD 179M in revenue and (HKD 1M) in net income.

Elegance Optical International Holdings Limited, an investment holding company, manufactures and trades in optical frames and sunglasses in Europe, the United States, the People's Republic of China, and internationally.

Interactive charts & full statements →

0907 Revenue & Earnings History — Annual Income Statement

Income statement2026-03-312025-03-312024-03-312023-03-312022-03-31
Total RevenueHKD 179MHKD 14MHKD 24MHKD 22M
Gross ProfitHKD 41MHKD 1MHKD 5MHKD 6M
Operating Income (EBIT)HKD 14M(HKD 17M)(HKD 17M)(HKD 8M)
Net Income(HKD 1M)(HKD 20M)(HKD 59M)(HKD 77M)

HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

0907 Free Cash Flow History

0907 Balance Sheet History

Balance sheet2026-03-312025-03-312024-03-312023-03-312022-03-31
Total AssetsHKD 241MHKD 76MHKD 92MHKD 148M
Total LiabilitiesHKD 243MHKD 79MHKD 74MHKD 62M

HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 0907 viewer.

Other Companies in Medical Instruments & Supplies

← 0902All “0-9” companies0909 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.